Eureka Genomics to Merge with Nanobac Pharma | GenomeWeb

NEW YORK (GenomeWeb News) – Eureka Genomics plans to merge with Nanobac Pharmaceuticals under a stock and cash deal, the bioinformatics company said today.

Under a memorandum of understanding, Eureka stockholders will receive new shares of Nanobac common stock and own 85 percent of the combined company, which will operate under the Eureka Genomics name. Nanobac has already provided Eureka with initial funds, and the deal is expected to close in the second quarter of 2009.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: a sequencing-based screen of Lyme disease-causing pathogen, the range of animals bitten by Anopheles darling mosquitoes in Peru, and more.

An NC State researcher is exploring the use of CRISPR-Cas3 as an anti-microbial, Gizmodo reports.

The Earth BioGenome Project plans to sequence all life on Earth, according to ScienceInsider.

For those who are concerned about Trump administration actions related to science, a new column in Scientific American has suggestions for ways to fight back.